Press release from Companies
Published: 2022-08-11 08:30:00
We are finally entering a very exciting period for the company, as we will soon have first patient in our pivotal trial 0205, a trial that will investigate the postoperative analgesic efficacy of CT001.
We obtained regulatory approval by the authorities and thereby green light at the end of June and have since then prepared the site and involved dental clinics. We are ready and hope to announce first patient within a few weeks. This will basically take the company to the next level as not that many companies are in a late-stage clinical development...
Upcoming top line results of Trial 0206 Developing the Team - welcome to Martin, head of CMC & Device Entrepreneurship award donated to Rigshospitalet For more information about Cessatech, please contact: About Cessatech
During this quarter (Q3) we also anticipate to announce the top-line results of trial 0206, the study completed recruitment earlier this year and is currently undergoing statistical analysis. The trial investigates pharmacokinetics of CT001 in children aged 1-17 undergoing elective surgical procedures. The results will be very important in the work going forward and we are very excited that we soon have the results.
CMC & Device development is instrumental, so we are very fortunate to have Martin joining us earlier this year. Martin has a Ph.D. in Chemistry and a postdoc from Harvard prior to joining Lundbeck where he worked for 14 years, while also obtaining a degree in Pharmaceutical Medicine. He is both as a CMC subject-matter-expert, has 12 years of project management experience & been involved in 15 IMPD/IND submissions.
We donated the prize money we won from the Rotary entrepreneurship award to Rigshospitalet and bought Toy's for the Children - children are often waiting or hospitalised for longer periods and especially if they are frequent visiting due to for instance chronic conditions. On the picture is Laura, and when the picture was taken, she had been anaesthetised for the 37th time at Rigshospitalet. Happy that we can make a small difference….and thanks to the Rotary Club for awarding and selecting us as district winners for our entrepreneurship.
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development.
